Lineage Cell Therapeutics Inc (AMEX:LCTX) has a beta value of 1.33 and has seen 1.2 million shares traded in the last trading session. The company, currently valued at $263.94M, closed the last trade at $1.40 per share which meant it lost -$0.04 on the day or -2.78% during that session. The LCTX stock price is -15.0% off its 52-week high price of $1.61 and 40.0% above the 52-week low of $0.84. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.44 million shares traded. The 3-month trading volume is 908.72K shares.
Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information
Sporting -2.78% in the red in last session, the stock has traded in the red over the last five days, when the LCTX stock price touched $1.40 or saw a rise of 10.26%. Year-to-date, Lineage Cell Therapeutics Inc shares have moved 28.44%, while the 5-day performance has seen it change -5.41%. Over the past 30 days, the shares of Lineage Cell Therapeutics Inc (AMEX:LCTX) have changed 23.89%. Short interest in the company has seen 9.98 million shares shorted with days to cover at 12.7.
Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts
Figures show that Lineage Cell Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 16.67% over the past 6 months, with this year growth rate of -41.67%, compared to 13.50% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are -33.30% and -33.30% for the next quarter. Revenue growth from the last financial year stood is estimated to be 95.40%.
6 analysts offering their estimates for the company have set an average revenue estimate of $1.36 million for the current quarter. 6 have an estimated revenue figure of $1.12 million for the next quarter concluding in Jun 2024. Year-ago sales stood $2.01 million and $3.23 million respectively for this quarter and the next, and analysts expect sales will shrink by -32.30% for the current quarter and -65.30% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 19.25% over the past 5 years.
LCTX Dividends
Lineage Cell Therapeutics Inc is expected to release its next earnings report between May 09 and May 13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders
Insiders own 4.13% of the company shares, while shares held by institutions stand at 43.96% with a share float percentage of 45.86%. Investors are also buoyed by the number of investors in a company, with Lineage Cell Therapeutics Inc having a total of 143 institutions that hold shares in the company. The top two institutional holders are Broadwood Capital, Inc. with over 34.94 million shares worth more than $49.26 million. As of Jun 29, 2023, Broadwood Capital, Inc. held 19.96% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 9.01 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $12.71 million and represent 5.15% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Jun 29, 2023, the former fund manager holds about 2.59% shares in the company for having 4.52 million shares of worth $6.38 million while later fund manager owns 2.54 million shares of worth $3.35 million as of Aug 30, 2023, which makes it owner of about 1.45% of company’s outstanding stock.
